TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07817251: Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

Sponsor: Novo Nordisk A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 210 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,135,960

Rescue Site Savings

+$6,694,448

Unlock Full NCT07817251 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07817251 Rescue Dossier →